Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Neoplasms × belzutifan × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Renal Cell 5 von Hippel-Lindau Disease 3 Pheochromocytoma 2 Paraganglioma 2 Kidney Neoplasms 2 Vulvar Neoplasms 1 Vaginal Neoplasms 1 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Recurrence 1 Ovarian Neoplasms 1 Neuroectodermal Tumors, Primitive 1 Neoplasms 1 Hemangioblastoma 1 Endometrial Neoplasms 1 Breast Neoplasms 1 Adenoma, Islet Cell 1

Interventions

Bevacizumab 45 Gemcitabine 44 Cyclophosphamide 39 Carboplatin 37 Docetaxel 34 Fluorouracil 32 Cisplatin 32 Paclitaxel 31 pembrolizumab 28 Oxaliplatin 25 Radiotherapy 24 Irinotecan 23 Leucovorin 22 Capecitabine 22 Dexamethasone 21 Cetuximab 21 Nivolumab 19 Pemetrexed 18 Drug Therapy 18 Doxorubicin 18 Erlotinib Hydrochloride 17 Trastuzumab 15 Rituximab 15 Prednisone 15 durvalumab 14 atezolizumab 13 Sorafenib 13 fludarabine 12 Lapatinib 12 Everolimus 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04976634 2025-04-06

MK-6482-016

Merck Sharp & Dohme LLC

Phase 2 Active not recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡